Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

hNPC-EX

Next Previous
X
Search
Drug Profile

hNPC-EX

Alternative Names: hNPC Exosome; Human Dopaminergic Neural Progenitor Cell exosome

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hopstem Biotechnology
  • Class Exosome therapies
  • Mechanism of Action Exosome replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Alzheimer's disease; Autistic disorder

Most Recent Events

  • 09 Jul 2024 Hopstem Biotechnology has patent protection for "Method for producing induced pluripotent stem cells by somatic cell reprogramming" and "Generation of neural progenitor cells from embryonic stem cells or induced pluripotent stem cells" in China (Hopstem Biotechnology website, July 2024)
  • 09 Jul 2024 Early research in Alzheimer's disease in China (unspecified route) (Hopstem Biotechnology Pipeline, July 2024)
  • 09 Jul 2024 Early research in Autistic disorder in China (unspecified route) (Hopstem Biotechnology Pipeline, July 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top